Navigation Links
Zyflamend inhibits 78 percent of prostate cancer cells

An article published in the October issue of the journal Nutrition and Cancer says that Zyflamend, an herbal extract from olive oil could end the search for a drug to beat prostate cancer.//

It was found that this element caused the prostate cancer cells to commit "suicide." The researchers report that the drug had the ability to inhibit 78 percent of the cancer cell growth plus it also caused "apoptosis". This is the natural process by which a cell dies. Cell death in this way is a physiological process and Zyflamend's ability to trigger this action bodes well for the future, according to the lead researcher in the study, Dr. Debra L. Bemis of Columbia University College of Physicians and Surgeons, New York. "Together, these results suggest that Zyflamend might have some chemopreventive utility against prostate cancer in men," she said.

It was also found that Zyflamend had both COX-1 and COX-2 inhibitory effects on the cancer cells and was shown to decrease the activity of both these enzymes in a dramatic manner in the laboratory setting. "We are currently conducting a Phase I clinical trial for men with a pre-cancerous lesion of the prostate -- prostatic intraepithelial neoplasia -- to gain some information as to Zyflamend's potential to prevent or slow... progression to prostate cancer," Dr. Bemis concluded.

The COX inhibitors are known to have some effect on prostate cancer cells, but are contraindicated in heart disease since they have adverse impact on the heart. Zyflamend was seen to have the similar chemical structure as that of Aspirin.
'"/>




Related medicine news :

1. Garlic inhibits fungal growth and protects food
2. Pharmacia may take 51.5 percent Abbott stake
3. NHS Forced to Borrow Money at Rates of 10 percent
4. Thirty percent of nurses distressed with verbal and physical abuse
5. 17 percent rise in childhood cancer cases due to modern lifestyles
6. Supercentenarian Center to study longevity
7. Better prostate cancer detection
8. Protective effects of tomatoes in prostate cancer
9. Early detection of prostate cancer
10. Fingerprinting prostate cancer
11. No link between blood groups and prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/12/2017)... WILMINGTON, Del. (PRWEB) , ... October 12, 2017 ... ... technology and advisory services for healthcare compliance program management, will showcase a range ... and National Association for Assisted Living (NCAL) Convention and Expo to be held ...
(Date:10/12/2017)... ... ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s premier ... of the shoulder pad. The shoulder pad provides optimal support and full contact ... using cold therapy. By utilizing ice and water that is circulated from an insulated ...
(Date:10/12/2017)... ... 12, 2017 , ... Dr. Parsa Mohebi, the Los Angeles ... to the newly revamped Cosmetic Town journal section, featuring articles written ... known as Follicular Unit Extraction (FUE). , Dr. Mohebi says “I ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and Grand Rapids-based workplace ... Brightest in Wellness® by Best and Brightest. OnSite Wellness will be honored at ... from 7:30 a.m. to 2 p.m. at the Henry Autograph Collection Hotel, located ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... of California Berkeley, and other leading institutions in announcing the launch of the ... to change the way animals are raised for food. , Founding members of ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... AVACEN Medical , Inc. (AVACEN) announced that ... New Product Innovation Award for Its fibromyalgia pain management ... medical device market research by Frost & Sullivan,s industry experts. ... pain relief product, the AVACEN 100, offers a safe and ... pain. ...
(Date:10/12/2017)... West Pharmaceutical Services, Inc. (NYSE: ... drug administration, today announced that it will release third-quarter ... October 26, 2017, and will follow with a conference ... 9:00 a.m. Eastern Time. To participate on the call, ... ID is 94093362. ...
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ® ... fulfilling the promise of precision medicine, today announced that ... Caris, Precision Oncology Alliance™ (POA) as its 17 th ... the St. Jude Crosson Cancer Institute will help develop ... use of tumor profiling, making cancer treatment more precise ...
Breaking Medicine Technology: